AI Analysis | Feedback

Here are 1-3 brief analogies for Liminatus Pharma:

• Like a very early-stage Genentech, focused entirely on developing a novel cancer therapy.
• Imagine a tiny Amgen, still deep in the lab researching a breakthrough cancer drug.
• Think of a startup version of Merck, solely dedicated to creating one experimental cancer treatment.

AI Analysis | Feedback

• CD47 Antibody (Drug Candidate): A high-affinity humanized anti-CD47 antibody being developed to block CD47-SIRPa interaction, aiming to restore anti-tumor function of innate immune cells for cancer therapy without causing hemagglutination or hemolysis.

AI Analysis | Feedback

Liminatus Pharma, Inc. (LIMN) is a pre-clinical stage biopharmaceutical company. At this stage of development, the company is focused on research and development of novel cancer therapies (specifically, a CD47 antibody) and has not yet commercialized any products. Therefore, Liminatus Pharma does not currently have major customers that purchase its therapies.

AI Analysis | Feedback

null

AI Analysis | Feedback

Chris Kim

Chris Kim was appointed CEO of Liminatus Pharma, Inc. in November 2022. He also serves as the company's Chairman. Previously, Mr. Kim served as IP counsel to global pharmaceutical companies such as Merck, Pfizer, GSK, Novartis, and Bayer. He was also a counsel for DeHeng Law Office NY. Mr. Kim holds a JD, LLM, and is an SJD candidate from the University of Pennsylvania Law School and Yonsei University. Under his leadership, Liminatus Pharma completed a business combination with Iris Acquisition Corp, a special purpose acquisition company backed by Arrow Capital, in April 2025.

Scott Dam

Scott Dam serves as the Chief Financial Officer of Liminatus Pharma, Inc. He has extensive experience in the financial sector, having served as Managing Director at Raymond James and Head of Asia Healthcare Investment Banking. Mr. Dam also held senior positions at Jefferies and Credit Suisse in the U.S. and Asia. His expertise includes cross-border mergers and acquisitions (M&A), capital markets, and strategic advisory within the healthcare and biopharma sectors. He holds an MBA from INSEAD and a CFA designation. Raymond James acted as a financial advisor to Liminatus during its business combination with Iris Acquisition Corp.

Beom Choi

Beom Choi serves as the Chief Technology Officer and a Member of the Scientific Advisory Board at Liminatus Pharma, Inc.

Byong Yoo

Byong Yoo is the Chief Science Officer and a Member of the Scientific Advisory Board for Liminatus Pharma, Inc. He previously served as a Principal Researcher at the National Cancer Center, Republic of Korea, for over 20 years. Mr. Yoo is an expert in biochemistry, proteomics, and metabolomics, with a focus on anticancer drug resistance and biomarker discovery. He has authored two books and over 130 publications, including in Nature, and has received multiple national awards.

Sang-jin Lee

Sang-jin Lee is the Head of Research & Development and a Member of the Scientific Advisory Board at Liminatus Pharma, Inc. He has served as the Director of Animal Experimental Facility of the Research Institute of the National Cancer Center, Republic of Korea, and as a Professor of the Graduate School of Cancer Science and Policy at the National Cancer Center, Republic of Korea. He also coordinated The Korean Association of Immune Cell Engineering and Therapy.

AI Analysis | Feedback

Key Risks to Liminatus Pharma (LIMN)

1. Clinical Development and Regulatory Approval Risk: As a pre-clinical stage biopharmaceutical company, Liminatus Pharma's primary asset, the CD47 antibody IBA101, faces substantial inherent risks associated with drug development and regulatory approval. The vast majority of drug candidates fail during preclinical or clinical trials, with only an estimated 3-5% of products progressing from preclinical testing to advanced clinical testing and approximately 20% advancing from Phase 1 trials to market approval. While Liminatus's IBA101 is designed to overcome historical toxicity issues of other CD47-targeting drugs by avoiding severe anemia and thrombocytopenia, success in early human studies and subsequent clinical trial phases is not guaranteed. Any failure in demonstrating safety or efficacy during clinical trials, or the inability to meet regulatory requirements, would severely impact the company's viability.
2. Funding and Capital Raising Risk: Liminatus Pharma operates as a pre-revenue company with significant ongoing research and development costs. Developing novel cancer therapies, particularly through extensive clinical trials, requires substantial capital investment over a long period. The company has faced liquidity challenges and a negative equity position. Although Liminatus recently completed a public offering, securing additional financing remains crucial for advancing its lead candidate, IBA101, through clinical development and toward potential commercialization. Failure to secure adequate funding in a cost-effective manner could lead to delays or the halt of its drug development programs.

AI Analysis | Feedback

AI Analysis | Feedback

The addressable market for Liminatus Pharma's main product, a humanized anti-CD47 antibody designed for novel cancer therapies, is the global anti-CD47 drugs market.

This market was estimated to be valued at approximately USD 0.1 billion in 2023 and is projected to grow significantly to reach USD 2.46 billion by 2032, exhibiting a compound annual growth rate (CAGR) of over 40% from 2025 to 2032. The market is driven by the increasing incidence of cancer globally and advancements in the development of novel cancer immunotherapies.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Liminatus Pharma (LIMN) over the next 2-3 years:

1. Advancement of its lead CD47 antibody, IBA101, through early-stage clinical trials. Liminatus Pharma is initiating a Phase 1 clinical trial for IBA101 in March 2026, initially focusing on lung cancer as a monotherapy and then in combination with existing immuno-oncology therapies. Successful progression through Phase 1 and potentially into Phase 2 within the next 2-3 years would be a significant value inflection point, making the asset more attractive for partnerships or further development which could generate milestone payments.
2. Progression of its GCC vaccine through ongoing Phase II clinical trials. The company is also developing a GCC vaccine, currently in Phase II trials for various cancers including colorectal, gastric, pancreatic, and esophageal cancers. Positive data and further advancement in these trials could lead to strategic partnerships or licensing agreements, providing revenue through upfront payments and development milestones.
3. Securing strategic partnerships and licensing agreements for its pipeline candidates. As a pre-clinical and early clinical-stage biopharmaceutical company, significant revenue growth is highly dependent on entering into collaboration or licensing deals with larger pharmaceutical companies. These agreements typically include upfront payments and subsequent milestone payments tied to the achievement of specific development, regulatory, or commercialization goals for IBA101 or the GCC vaccine. Liminatus Pharma has already signed a Memorandum of Understanding for a $30 million equity investment and plans discussions for further strategic cooperation, indicating an active pursuit of external partnerships.

AI Analysis | Feedback

Share Issuance

• In February 2026, Liminatus Pharma completed a public offering of common stock, pre-funded warrants, and common stock purchase warrants at a combined price of $0.29 per share (or $0.2899 per pre-funded warrant) and warrant, generating gross proceeds of approximately $4.0 million. Net proceeds amounted to about $3.46 million after fees and expenses, with the potential for an additional $6.0 million if all investor warrants are fully exercised for cash.
• The February 2026 offering included the issuance of 8,270,000 common shares, 5,543,000 pre-funded warrants, and 13,813,000 common stock purchase warrants for up to 20,719,500 shares, along with 690,650 placement agent warrants. This offering contributed to significant dilution, following a 528.6% increase in total shares outstanding in the preceding year.
• Liminatus Pharma's common stock and public warrants began trading on The Nasdaq Stock Market on May 1, 2025, after the company, formerly Iris Parent Holding Corp., consummated a business combination to acquire Liminatus Pharma, LLC on April 30, 2025.

Inbound Investments

• On October 30, 2025, Liminatus Pharma signed a Memorandum of Understanding (MOU) with Capital Trust Group Limited for a USD 30,000,000 equity financing. This investment, structured via an earn-out mechanism, is intended to support the company's research and development of advanced immunotherapy assets.
• In July 2025, Liminatus Pharma announced it was evaluating the formation of a digital asset investment vehicle aimed at targeting up to $500 million in capital strategies.
• Liminatus Pharma initiated a strategic review of a blockchain-integrated treasury strategy in July 2025, as part of exploring alternative capital strategies.

Capital Expenditures

• In the last 12 months, capital expenditures for Liminatus Pharma were -$13,108.
• Proceeds from the February 2026 public offering are earmarked for funding clinical trials, research and development, sales and marketing, and general working capital needs.